Biofrontera

Ameluz Expansion Will Harness Secular Trends In Dermatology

AnalystHighTarget

Not Invested

Community Contributor

Published

27 Aug 25

AnalystHighTarget's Fair Value

US$10.00

90.2% undervalued

11 Sep

US$0.98

-16.5%

3.5%

-16.5%

3.5%

You can edit this narrative until Aug 27 9:24 PM. Then, changes will post as Updates.

Author's Valuation

US$1090.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$10

90.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

22.67%

Pharma revenue growth rate

0.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$33.15m

Earnings '28

8.61x

PE Ratio '28

US$285.31m

Market Cap '28

US$285.31m

Market Cap '28

23.44m

No. shares '28

US$12.17

Share Price '28

US$12.17 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$10.00

Fair Value '25